Daclatasvir and Asunaprevir Combination Therapy-induced Hepatitis and Cholecystitis with Coagulation Disorder due to Hypersensitivity Reactions

Yuichi Miyashima, Yuichi Honma, Koichiro Miyagawa, Shinji Oe, Michio Senju, Michihiko Shibata, Masaaki Hiura, Shintaro Abe and Masaru Harada

Abstract

A 70-year-old woman with chronic hepatitis C was admitted to our hospital due to liver injury, cholecystitis, and disseminated intravascular coagulation with a fever and skin rash. She had been on a combination regimen of daclatasvir and asunaprevir for 2 weeks of a 24-week regimen. Because of the symptoms, laboratory findings, results of a drug-induced lymphocyte stimulation test, and pathological findings of liver biopsy, we diagnosed her with drug-induced liver injury. Although daclatasvir and asunaprevir combination therapy is generally well-tolerated, some serious adverse effects have been reported. Our findings indicate that immunoallergic mechanisms were associated with daclatasvir and asunaprevir-induced liver injury.

Key words: asunaprevir, chronic hepatitis C, complement deficiency, daclatasvir, disseminated intravascular coagulation

(Intern Med 55: 3595-3601, 2016)
(DOI: 10.2169/internalmedicine.55.7347)

Introduction

The combination therapy of daclatasvir, a hepatitis C virus (HCV) NS5A inhibitor, and asunaprevir, a second-generation NS3/4A protease inhibitor, was approved in July 2014 in Japan as the first interferon (IFN)-free therapy for chronic hepatitis C (CHC) caused by HCV genotype 1b. This combination therapy has been shown to achieve a high rate of sustained virological response (SVR) in null responders to IFN based therapy and populations ineligible or intolerant to IFN (1). An open-label phase-III clinical trial demonstrated an SVR rate of 85% after 24 weeks of daclatasvir and asunaprevir combination therapy (2). The common side effects are nasopharyngitis, elevation of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), headache, diarrhea and pyrexia and serious adverse events are reported in 5.9% of patients during this treatment. About 91% of the patients with grade 3 or 4 ALT and AST elevation discontinued the treatment due to adverse effects (2). However, the discontinuation rate of this treatment due to side effects is lower than in conventional IFN-based therapies. In spite of its high tolerability, some patients on daclatasvir and asunaprevir therapy have to stop this treatment due to severe side effects. A previous report described a patient who discontinued this therapy and started corticosteroid treatment after developing immunoallergic hepatitis (3). However, details regarding the mechanisms of daclatasvir and asunaprevir combination therapy-induced liver injury remain unclear, and elucidation of the mechanisms of the associated severe adverse effects is urgently needed.

We herein report a patient receiving daclatasvir and asunaprevir combination therapy who developed drug-induced liver injury, cholecystitis, and disseminated intravascular coagulation (DIC), in whom immunoallergic mechanisms were considered to be related to the liver injury.

Case Report

A 70-year-old woman with CHC was admitted to our hospital for general fatigue and a fever. She had been started on a combination therapy of daclatasvir (60 mg/day) and...
asunaprevir (200 mg/day) at our hospital 2 weeks earlier, for a planned total of 24 weeks. She never received antiviral therapy for CHC. She had a history of drug allergy to some kinds of antibiotics but had no allergic diseases. The patient had a surgical history of ovarian tumor and blood transfusion at age 17. She was not a habitual drinker and did not take other drugs. There was no family history of liver diseases. The laboratory findings before starting the antiviral therapy are shown in Table 1. Serum ALT was 113 U/L, AST was 95 U/L, and HCV RNA was 6.1 log IU/mL. Her HCV genotype was 1b. Direct sequencing and a cycling-probe analysis did not show a Y93H or L31 mutation in the NS5A region of the HCV RNA. The white blood cell (WBC) count was 5,300/mm$^3$, and the eosinophil count was 461/mm$^3$. The combination therapy of daclatasvir and asunaprevir effectively improved the serum ALT (64 U/L) and AST (39 U/L) levels and decreased the HCV RNA (1.6 log IU/mL) on Day 8 of the combination therapy.

The clinical course of the present patient is shown in Fig. 1 and 2. On Day 11 of the therapy, she developed general fatigue, a fever (38.6°C), and headache without nasopharyngitis or jaundice. On Day 14, a physical examination after admission showed tenderness in the right hypochondrium and palpable liver in the epigastrium. No findings of hepatic encephalopathy were evident. A rash covering the whole body was observed, including the face, trunk, and extremities, up to approximately 50% of the body surface without skin peeling or mucous membrane ulceration (Fig. 3).

The laboratory data on admission are shown in Table 2, with details as follows: the levels of ALT (102 U/L), AST (40 U/L), γ-GTP (82 U/L), and C-reactive protein (CRP) (1.65 mg/dL) were elevated, and the HCV RNA level was markedly decreased (undetectable) compared with her base-
line values. The total bilirubin (1.1 mg/dL) and alkaline phosphatase (ALP) (220 U/L) levels were not elevated, but the ammonia (NH₃) (72 μg/dL) level was slightly elevated. The findings for hepatitis B surface antigen, anti-hepatitis A virus IgM, and anti-hepatitis E virus IgA antibody were negative, as were the findings for anti-cytomegalovirus (CMV) IgM and anti-Epstein-Barr virus (EBV) IgM antibody, while the findings for anti-CMV IgG, anti-EBV IgG, and anti-EBV-determined nuclear antigen (EBNA) antibody were positive. The findings for anti-human herpes virus (HHV) 1 and 2 IgM-antibody were negative, while those for IgG-antibody was positive. The findings for HHV 6 DNA were negative, as were the findings for anti-nuclear antibody, while the findings for IgG, IgA and IgM levels were within the normal ranges. However, the IgE level was elevated (503 U/mL). The WBC count (14,000/mm³) and eosinophil count (1,820/mm³) were increased, while the platelet (PLT) count was unchanged (44,000/mm³). Coagulation tests revealed a decrease in the % of prothrombin time (PT) (49.9%), PT-international normalized ratio (INR)
Table 2. The Laboratory Data on Admission.

| Hematology | Coagulation |
|------------|-------------|
| WBC 14,000 /μL | 99 mg/dL | PT 49.9% |
| Neut 68.9% | 80 mg/dL | APTT 40.9 sec |
| Eos 13.0% | 15 mg/dL | Fibrinogen 414 mg/dL |
| Baso 0.0% | 32 mg/dL | D-dimer 1.6 μg/mL |
| Lympho 12.4% | 3.8 mg/dL | AT-III 53% |
| RBC 389 × 10^6/μL | K | Virus markers |
| Hb 12.5 g/dL | Cl | HAV-IgM (-) |
| Hct 36.1% | Ferritin | HBsAg (-) |
| PLT 4.4 × 10^11/μL | NH₃ | HCV RNA undetectable |
| Biochemistry | Serology |
| TP 6.4 g/dL | CRP | 1.65 mg/dL | HEV-IgA (-) |
| Alb 3.1 g/dL | ANA | <40 x | EBV-IgM (-) |
| T-Bil 1.1 mg/dL | IgG | 1,265 mg/dL | EBV-IgG (+) |
| D-Bil 0.8 mg/dL | IgA | 153 mg/dL | EBNA (+) |
| AST 40 IU/L | IgM | 255 mg/dL | CMV-IgM (+) |
| ALT 102 IU/L | IgE | 503 U/mL | CMV-IgG (+) |
| LDH 170 IU/L | C3 | 113 mg/dL | HHV1-IgM (-) |
| ALP 220 IU/L | C4 | <5.0 mg/dL | HHV2-IgM (-) |
| γ-GTP 63 IU/L | CH50 | <5.0 U/mL | HHV6 DNA undetectable |

(1.55), and anti-thrombin III (53%). The levels of fibrin/fibrinogen degradation product (FDP) (8.9 μg/mL) and d-dimer (1.6 μg/mL) were elevated. In addition, the levels of serum complements, C4 (<5.0 mg/dL), and 50% hemolytic unit of complement (CH50) (<5.0 U/mL) were quite low, but C3 (113 mg/dL) and C1q (<1.5 μg/mL) were within the normal ranges.

Abdominal ultrasonography and contrast-enhanced computed tomography (CT) revealed hepatomegaly, dullness of the edge and periportal collar signs in the liver, and marked wall thickness and sludge accumulation of the gallbladder (Fig. 4). A small amount of ascites in surface of the liver and pleural effusion in the right thoracic cavity were detected. Hematoxylin and eosin staining of liver biopsy before the initiation of the combination therapy showed moderate chronic inflammatory infiltrates in the expanded portal areas with mild fibrosis (Fig. 5a). Liver biopsy performed on admission showed inflammatory infiltrate of eosinophils, which had not been detected just before starting the combination therapy. Lymphocytes in the hepatic lobes and portal areas with interface hepatitis and mild fibrosis were demonstrated (Fig. 5b-d). No increases were noted in the levels of reticular fiber and collagen fiber on silver impregnation staining (Fig. 5e). Periodic acid schiff with diastase digestion (D-PAS) staining showed increased numbers of Kupffer cells in the sinusoid, indicating acute liver injury (Fig. 5f). The findings from a drug-induced lymphocyte stimulation test (DLST) for both daclatasvir (stimulation index; 265%) and asunaprevir (stimulation index; 205%) were positive.

Given the above findings, we diagnosed her with drug-induced liver injury, cholecystitis, and DIC due to daclatasvir and asunaprevir combination therapy and immediately stopped both drugs. The diagnosis of DIC was based on the DIC diagnostic criteria issued by the Japanese Association of Acute Medicine, including the findings of systemic inflammatory response syndrome (SIRS) (WBC >12,000/mm³, heart rate >90/min, respiratory rate >20/min), thrombocytopenia (PLT <80,000/mm³), and elevated PT-INR (PT-INR >1.2), and by the Japanese Ministry and Health, Labor and Welfare, including primary disease, thrombocytopenia (PLT <50,000/mm³) and elevated PT-INR (PT-INR >1.25). In addition, the elevated FDP and d-dimer levels and the decreased AT-III activity supported the diagnosis of DIC. The symptoms, including a fever, skin rash, abdominal pain in the right hypochondrium, and epigastralgia, were resolved after the discontinuation of daclatasvir and asunaprevir. The laboratory examinations revealed improvement in the serum CRP, WBC count, thrombocytopenia, and coagulation abnormalities, but the elevation of ALT and AST levels and eosinophilia persisted for four weeks. The ultrasonography findings of hepatomegaly and thickening of the gallbladder wall gradually improved after discontinuing the therapy. HCV RNA remained below the detectable limit (<1.2 log IU/mL) 4 weeks after stopping daclatasvir and asunaprevir. However, because the HCV RNA subsequently increased (5.0 log IU/mL) at 8 weeks after discontinuing the combination therapy, the patient did not achieve an SVR.

Discussion

The combination therapy of daclatasvir and asunaprevir was the first IFN-free oral treatment approved in Japan. To date, this combination therapy has been introduced in many patients with CHC, and a high SVR rate has been achieved. A low rate of serious adverse effects and good tolerability are among the promising features of this therapy; however, elevated levels of ALT and AST occur in about 16% and 13% of patients, respectively (2). The incidence of adverse events, such as the elevation of levels of aminotransferases, is reported to differ between Japanese and European patients (4). A similar ethnic difference has also been observed in the occurrence of side ef-
effects. However, although a previous report had suggested an immunooallergic mechanism for daclatasvir and asunaprevir combination therapy-induced hepatic injury (3), the mechanisms of daclatasvir and asunaprevir combination therapy-induced hepatic injury are poorly understood.

The present case was diagnosed as liver injury, cholecystitis, and DIC based on the findings from laboratory examinations and the abdominal physical and imaging findings. The ALT elevation and eosinophilia in this patient persisted more than five weeks after stopping the combination therapy. The clinical course of drug-induced liver injury after discontinuation of causing drugs seems to be variable. The elevation of liver enzymes with drug-induced liver injury has been reported to persist for several months after discontinuing the causal agents (5). Previous reports have been shown that the severity grading of rash associated with telaprevir, another NS3/4A protease inhibitor for CHC (6, 7). The skin findings for the present case support a moderate (grade 2) but not severe grade on the telaprevir-associated rash severity scale.

As previously reported (3), we also suspected drug-induced hypersensitivity syndrome (DIHS) based on the symptoms, such as a fever and skin rash, and the laboratory findings, including eosinophilia. DIHS is characterized by a skin rash, a fever, leukocytosis with eosinophilia or atypical lymphocytosis, and the liver dysfunction (8, 9). The diagnostic criteria for DIHS include maculopapular rash developing over three months after starting drugs, lymphadenopathy, a fever, leukocytosis, hepatitis, and HHV 6 reactivation.
The diagnosis of DIHS is confirmed by the presence of five of the six symptoms (10). The liver dysfunction occurs in up to 70% of DIHS (10). The eosinophilia may often be delayed for several weeks and occur even after the elevated liver enzyme levels have returned to baseline (10). In the present case, the allergic symptoms, aminotransferase elevation, and eosinophilia were evident. However, the onset time of the symptoms and absence of HHV 6 reactivation did not meet the criteria. We considered the persistent elevation of ALT and eosinophilia in the present case to correspond to the course of immune-mediated drug-induced liver injury.

Interestingly, the findings for the DLST for both daclatasvir and asunaprevir were strongly positive. The sensitivity of DLST is considered to be about 50%. Given that the DLST is considered to be useful for diagnosing drug-induced liver injury (11, 12), we considered that daclatasvir and asunapre-
asunaprevir-induced liver injury. Our present findings will enable the formulation of a new hypothesis regarding the mechanisms of daclatasvir and asunaprevir-induced liver injury.

The authors state that they have no Conflict of Interest (COI).